Nektar Therapeutics earnings were -$119.0M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. The latest NKTR earnings report on Dec 31, 2024 announced Q4 2024 earnings of $7.3M, down 119.6% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, NKTR reported annual earnings of -$119.0M, with -56.9% growth. The next NKTR earnings date is May 7, 2025.
Nektar Therapeutics Earnings Reports & History FAQ
What were Nektar Therapeutics's earnings last quarter?
On NKTR's earnings call on Invalid Date, Nektar Therapeutics (NASDAQ: NKTR) reported Q4 2024 earnings per share (EPS) of $0.04, up 118.18% year over year. Total NKTR earnings for the quarter were $7.26 million. In the same quarter last year, Nektar Therapeutics's earnings per share (EPS) was -$0.22.
The next NKTR earnings call is Invalid Date. Add NKTR to your watchlist to be reminded of Nektar Therapeutics's next earnings date.
Is Nektar Therapeutics profitable or losing money?
As of the last Nektar Therapeutics earnings report, Nektar Therapeutics is currently losing money. Nektar Therapeutics's net profit (also called net income) for the twelve months ending Dec 31, 2024 was -$118.96 million, a 56.91% decrease year over year.
What was NKTR's earnings growth in the past year?
As of Nektar Therapeutics's earnings date in Invalid Date, Nektar Therapeutics's earnings has grown year over year. NKTR earnings in the past year totalled -$118.96 million.
What are Nektar Therapeutics's earnings expectations?
The current EPS estimate for Nektar Therapeutics's earnings report in Invalid Date is -$0.19.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.